Mauna Kea announced a € 7.5m strategic investment from Johnson & Johnson Innovation - JJDC, Inc. ("JJDC" - part of Johnson & Johnson ("J&J")) which provides further funding for the development of the Cellvizio platform and will allow the company to execute its strategic growth initiatives as it expands into the interventional pulmonology ("IP") market. A subscription price of €1.40, represents a c.30% premium to the previous close. The agreement also provides J&J wit
17 Dec 2019
J&J deal highlights promise of Cellvizio
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
J&J deal highlights promise of Cellvizio
Mauna Kea Technologies SA Class O (0P5I:LON) | 0 0 0.2% | Mkt Cap: 75.0m
- Published:
17 Dec 2019 -
Author:
KIERON BANERJEE -
Pages:
5
Mauna Kea announced a € 7.5m strategic investment from Johnson & Johnson Innovation - JJDC, Inc. ("JJDC" - part of Johnson & Johnson ("J&J")) which provides further funding for the development of the Cellvizio platform and will allow the company to execute its strategic growth initiatives as it expands into the interventional pulmonology ("IP") market. A subscription price of €1.40, represents a c.30% premium to the previous close. The agreement also provides J&J wit